Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the ...
24/7 Wall St.6d
Novo Nordisk (NVO) Price Prediction and Forecast 2025-2030 (March 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Becker's Hospital Review13d
Why Ozempic might help tackle aging
Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Hims & Hers Health (HIMS) Shares Spike with Compounded Drug Strategy for GLP-1s
Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...
Mounjaro hits shelves in India: How Eli Lilly’s weight loss drug compares with Ozempic — price, side effects and more
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...
CNBCTV181d
Eli Lilly’s Mounjaro targets India’s $150 billion weight-loss market amid rising diabetes crisis
Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...